Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Myopia
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Open prospective clinical trial with historical controlMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 7 years and 17 years
- Gender
- Both males and females
Description
The study is designed to test the following hypotheses: 0.01% atropine one drop nightly is safe and with no significant side effects. nightly instillations of 0.01% atropine does not influence tear production. 0.01% atropine one drop nightly reduces the progression of childhood myopia in Russian chi...
The study is designed to test the following hypotheses: 0.01% atropine one drop nightly is safe and with no significant side effects. nightly instillations of 0.01% atropine does not influence tear production. 0.01% atropine one drop nightly reduces the progression of childhood myopia in Russian children. nightly instillations of 0.01% atropine decreases the manifest refraction and, consequently, difference between manifest and cycloplegic refractions. effectiveness of 0.01% atropine depends on the age and myopia progression rate at the time the therapy was started.
Tracking Information
- NCT #
- NCT04338373
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon